Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Marvel Biotechnology is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution of this portfolio involves 1 distinct examiner and 1 distinct art unit, indicating a very narrow scope of current activity. In the pharmaceutical sector, this level of concentration suggests a specific focus on a single drug candidate or biological process.
BRADLEY SCOTT MAYHEW is the busiest examiner for the company, with 1 pending office action currently assigned. This 1 busiest examiner pending action represents the total volume of pending actions for the company. Consequently, the company's immediate patenting outcomes are tied to the decisions of this single examiner. The involvement of 1 distinct art unit implies that the company is not currently facing the complexities of multi-unit examination, which can often occur in broader biotechnological patent applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MAYHEW, BRADLEY SCOTT | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18715964 | PURINE COMPOUNDS FOR TREATING DISORDERS | MAYHEW, BRADLEY SCOTT | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18715964 | PURINE COMPOUNDS FOR TREATING DISORDERS | MAYHEW, BRADLEY SCOTT | 1621 | §103§112DP | Non-Final OA | — | Pending | Jun 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMarvel Biotechnology has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Bradley Scott Mayhew has the most, with 1 of Marvel Biotechnology's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
